Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
Kontoghiorghes
G J
GJ
Kolnagou
A
A
D015913:Chelation Therapy / Q000379:methods; D000077543:Deferiprone; D003676:Deferoxamine / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006207:Half-Life; D006801:Humans; D007501:Iron / Q000378:metabolism; D007502:Iron Chelating Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011728:Pyridones / Q000493:pharmacokinetics / Q000627:therapeutic use*; D017086:beta-Thalassemia / Q000188:drug therapy* / Q000378:metabolism
D007502:Iron Chelating Agents; D011728:Pyridones; D000077543:Deferiprone; D007501:Iron; D003676:Deferoxamine